ROYAL LONDON ASSET MANAGEMENT LTD
Position in NBIX — Neurocrine Biosciences Inc
CIK 863748
UNITED KINGDOM, X0
Position in NBIX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$9,229,756
+$2,015,279 QoQ
Shares Held
54,763
0.0% QoQ
Ownership
0.054%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#163
of 768 holders
Holding Since
Jun 2023
13 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026ROYAL LONDON ASSET MANAGEMENT LTD holds $27,766,715 across 4 Drug Manufacturers - Specialty & Generic names. NBIX ranks #2 (33.2% of the industry book) .
All Filings in NBIX
Export CSV
13 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,229,756 | 54,763 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $7,214,477 | 54,763 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $7,767,036 | 54,763 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $7,553,005 | 53,804 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $6,762,624 | 53,804 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $6,301,435 | 56,975 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $7,034,254 | 51,533 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $5,937,632 | 51,533 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $6,260,267 | 45,473 | Shares | Sole | 2024-08-07 | |
| 2024-03-31 | $6,271,636 | 45,473 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $4,248,996 | 32,248 | Shares | Sole | 2024-03-01 | |
| 2023-09-30 | $3,627,900 | 32,248 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $2,817,495 | 29,878 | Shares | Sole | 2023-08-11 | |
| No filing history on record for this holder in this stock. | ||||||